During the past decade, Parker Jewish Institute for Health Care and Rehabilitation conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Parker Jewish Institute for Health Care and Rehabilitation" #1 sponsor was "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials, followed by "CardioKine Inc." with 1 trials sponsored, "Cerecin" with 1 trials sponsored, "H. Lundbeck A/S" with 1 trials sponsored and "Neurotrope Bioscience, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Parker Jewish Institute for Health Care and Rehabilitation" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Cardiokine Biopharma, LLC" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Parker Jewish Institute for Health Care and Rehabilitation" are "Alzheimer's Disease" (5 trials), "Chronic Kidney Disease" (1 trials), "Chronic Renal Failure" (1 trials), "Euvolemic Hyponatremia" (1 trials) and "Symptomatic Neurogenic Orthostatic Hypotension" (1 trials). Many other conditions were trialed in "Parker Jewish Institute for Health Care and Rehabilitation" in a lesser frequency.

Most popular intervention types in "Parker Jewish Institute for Health Care and Rehabilitation" are "Drug" (7 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Bapineuzumab 0.5 mg/kg" (2 trials), "Bapineuzumab 1.0 m/kg" (2 trials), "Placebo Control" (2 trials) and "AC-1204" (1 trials). Other intervention names were less common.

The vast majority of trials in "Parker Jewish Institute for Health Care and Rehabilitation" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Parker Jewish Institute for Health Care and Rehabilitation". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Parker Jewish Institute for Health Care and Rehabilitation, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Parker Jewish Institute for Health Care and Rehabilitation, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".